Biohaven Pharmaceutical Holding Co Ltd.
DelistedCIK 1689813fmd_0G0Q49QG2RA7YZV379MEAZM7BNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2022, 27 periods
Latest annual · FY2021
Millions- Total revenues
- 463
- Gross profit
- 371
- Operating income
- (704)
- Net income
- (847)
- Free cash flow
- (833)
Latest quarter · Q2 FY2022
Millions- Total revenues
- 215
- Gross profit
- 179
- Operating income
- (290)
- Net income
- (442)
- Free cash flow
- (136)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2018 to FY2021
- n/m
- Revenue, 5 yearsFY2016 to FY2021
- n/m
- Net income, 5 yearsFY2016 to FY2021
- n/m
Biohaven Pharmaceutical Holding Co Ltd. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Revenue | $462.5 million | $63.6 million | +626.9% | 10-K 2022-02-25 · proof |
| Gross profit | $370.8 million | $45.9 million | +707.4% | 10-K 2022-02-25 · proof |
| Operating income | -$704 million | -$645.4 million | 10-K 2022-02-25 · proof | |
| Net income | -$846.6 million | -$766.8 million | 10-K 2022-02-25 · proof | |
| Cash from operating activities | -$831.1 million | -$702.9 million | 10-K 2022-02-25 · proof | |
| Free cash flow | -$832.8 million | -$705.2 million | 10-K 2022-02-25 · proof | |
| Total assets | $1.1 billion | $687 million | +56.8% | 10-K 2022-02-25 · proof |
| Total liabilities | $1.8 billion | $1 billion | +72.7% | 10-K 2022-02-25 · proof |
| Cash and cash equivalents | $171.9 million | $132.1 million | +30.1% | 10-K 2022-02-25 · proof |
- What was Biohaven Pharmaceutical Holding Co Ltd.'s revenue in fiscal 2021?
- Biohaven Pharmaceutical Holding Co Ltd. reported revenue of $462.5 million for fiscal 2021 (the year ended Dec 31, 2021), against $63.6 million the year before (+626.9%). Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What was Biohaven Pharmaceutical Holding Co Ltd.'s gross profit in fiscal 2021?
- Biohaven Pharmaceutical Holding Co Ltd. reported gross profit of $370.8 million for fiscal 2021 (the year ended Dec 31, 2021), against $45.9 million the year before (+707.4%). Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What was Biohaven Pharmaceutical Holding Co Ltd.'s operating income in fiscal 2021?
- Biohaven Pharmaceutical Holding Co Ltd. reported operating income of -$704 million for fiscal 2021 (the year ended Dec 31, 2021), against -$645.4 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What was Biohaven Pharmaceutical Holding Co Ltd.'s net income in fiscal 2021?
- Biohaven Pharmaceutical Holding Co Ltd. reported net income of -$846.6 million for fiscal 2021 (the year ended Dec 31, 2021), against -$766.8 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What was Biohaven Pharmaceutical Holding Co Ltd.'s cash from operating activities in fiscal 2021?
- Biohaven Pharmaceutical Holding Co Ltd. reported cash from operating activities of -$831.1 million for fiscal 2021 (the year ended Dec 31, 2021), against -$702.9 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What was Biohaven Pharmaceutical Holding Co Ltd.'s free cash flow in fiscal 2021?
- Biohaven Pharmaceutical Holding Co Ltd. reported free cash flow of -$832.8 million for fiscal 2021 (the year ended Dec 31, 2021), against -$705.2 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What are Biohaven Pharmaceutical Holding Co Ltd.'s total assets?
- As of Dec 31, 2021, Biohaven Pharmaceutical Holding Co Ltd. reported total assets of $1.1 billion, against $687 million a year earlier (+56.8%). Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What are Biohaven Pharmaceutical Holding Co Ltd.'s total liabilities?
- As of Dec 31, 2021, Biohaven Pharmaceutical Holding Co Ltd. reported total liabilities of $1.8 billion, against $1 billion a year earlier (+72.7%). Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
- What are Biohaven Pharmaceutical Holding Co Ltd.'s cash and cash equivalents?
- As of Dec 31, 2021, Biohaven Pharmaceutical Holding Co Ltd. reported cash and cash equivalents of $171.9 million, against $132.1 million a year earlier (+30.1%). Source: the 10-K filed with the SEC on Feb 25, 2022. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1689813&period_type=annual&limit=5"Information only, not investment advice.